作者: Guru Sonpavde , Myrna M. Khan , Robert S. Svatek , Richard Lee , Giacomo Novara
DOI: 10.1111/J.1464-410X.2010.09902.X
关键词:
摘要: Study Type – Therapy (individual cohort)
Level of Evidence 2b
What’s known on the subject? and What does study add?
Patients with urothelial carcinoma bladder (UCB) pathological (p) stage T2N0 disease exhibit a range clinical outcomes an overall estimated 10–25% experiencing recurrence death after radical cystectomy (RC). Nomograms to prognosticate UCB post-RC have been developed in heterogeneous datasets patients across different stages do not address factors unique pT2N0 disease.
A user-friendly prognostic risk model was devised for undergoing RC based residual at (pT2a, pT2b,